{
    "other_tests": [
        {
            "procedure_name": "Whole-exome sequencing",
            "date": "Not specified",
            "findings": "Identified compound heterozygous CLDN10 sequence variants [c.446C.G (p.Pro149Arg) and c.465-1G.A (p.Glu157_Tyr192del)] in patient 1 and [c.446C.G (p.Pro149Arg) and c.217G.A (p.Asp73Asn)] in patient 2.",
            "changes_over_time": "Not specified"
        },
        {
            "procedure_name": "Thiazide responsiveness testing",
            "date": "2012",
            "findings": "Exaggerated response rather than the generally blunted response expected in Gitelman syndrome.",
            "changes_over_time": "Not specified"
        },
        {
            "procedure_name": "Furosemide response testing",
            "date": "2012",
            "findings": "Exaggerated response, which can be blunted in patients with Bartter syndrome.",
            "changes_over_time": "Not specified"
        },
        {
            "procedure_name": "DDAVP response testing",
            "date": "Not specified",
            "findings": "Reduced response to DDAVP, indicative of disturbed concentrating ability due to insufficient buildup of interstitial osmolality.",
            "changes_over_time": "Not specified"
        }
    ]
}